ArticlePostepy w kardiologii interwencyjnej = Advances in interventional cardiology2026
Complete versus culprit only revascularization in young STEMI patients with multivessel disease.
Article in Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: There are still uncertainties regarding revascularization strategies in younger ST segment elevation myocardial infarction (STEMI) patients, largely due to limited data in this specific population. Aim: To determine whether complete revascularization reduces major adverse cardiovascular events (MACEs) and all cause mortality compared to culprit only percutaneous coronary intervention (PCI) in cases of STEMI among patients with multivessel disease. Material and methods: In this single center retrospective cohort study, we examined 431 STEMI patients treated between January 2022 and December 2023. Among these, 219 had undergone culprit only while 212 had received complete revascularization. Baseline demographics, angiographic and procedural variables, pharmacotherapy, laboratory, and echocardiographic data were collected. The primary endpoint was incidence of MACE, and the secondary endpoint was all cause mortality. Independent predictors of MACE and death were determined. Results: The median age was 49 years (IQR 46-50), and 89.1% were male. MACE occurred in 135 (31.3%) patients, with higher incidence in the culprit only group ( Conclusions: In young STEMI patients with multivessel disease, complete revascularization significantly reduces MACE compared to culprit-only PCI. Renal dysfunction and impaired left ventricular ejection fraction independently predict adverse outcomes, while b-blocker and antilipemic therapy are associated with improved survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.